A. Schomburg

发表

Clinical Application of 18FDG-PET in the Assessment of Head and Neck Tumors

H. Biersack, H. Bender, H. Straehler-Pohl, 1999 .

In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.

J. Buer, S. Duensing, S. Vocke, 1994, Cancer biotherapy.

Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice

H. Biersack, H. Bender, P. Oehr, 1997, Diseases of the colon and rectum.

Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer

H. Biersack, H. Bender, H. Palmedo, 1996, European Journal of Nuclear Medicine.

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.

S. Duensing, M. Volkenandt, S. Chaitchik, 1995, European journal of cancer.

18FDG PET and acetazolamide-enhanced99mTc-HMPAO SPET in systemic lupus erythematosus

J. Ruhlmann, H. Biersack, F. Grünwald, 1995, European Journal of Nuclear Medicine.

Effects of diagnostic application of monoclonal antibody on survival in melanoma patients.

U. Reinhold, H. Biersack, H. Bender, 1997, Hybridoma.

Interleukin-2 and other cytokines

H. Kirchner, H. Poliwoda, J. Atzpodien, 1993 .

Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferonα: Evidence of a risk/benefit advantage of subcutaneous therapy

H. Kirchner, J. Atzpodien, A. Schomburg, 2005, Journal of Cancer Research and Clinical Oncology.

Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.

M. Volkenandt, H. Kirchner, A. Franzke, 1993, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Possible role of FDG-PET in the evaluation of urologic malignancies.

J. Ruhlmann, P. Albers, H. Biersack, 1997, Anticancer research.

Cytokine-based biotherapy of gastrointestinal tumors

M. Manns, J. Buer, S. Duensing, 1994, The clinical investigator.

Outpatient Therapy of Advanced Malignancies Using Recombinant Interleukin-2 and Recombinant Interferon-α With or Without Chemotherapy

H. Kirchner, H. Poliwoda, T. Menzel, 1992 .

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.

H. Kirchner, H. Poliwoda, T. Menzel, 1992, Natural immunity.

Cytokines and infection in cancer patients

H. Kirchner, J. Atzpodien, A. Schomburg, 1992, The Lancet.

Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.

E. Lopez Hänninen, H. Kirchner, H. Poliwoda, 1993, Acta haematologica.

Regional cerebral blood flow single-photon emission tomography with 99mTc-HMPAO and the acetazolamide test in the evaluation of vascular and Alzheimer’s dementia

László Pávics, Karl Reichmann, Frank Grünwald, 1999, European Journal of Nuclear Medicine.

Technetium-99m-MIBI scintimammography for suspicious breast lesions.

D Krebs, H. Biersack, H. Palmedo, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Clinical and preclinical evaluation of recombinant PEG-IL-2 in human.

H. Kirchner, H. Poliwoda, T. Menzel, 1993, Cancer biotherapy.

Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization orocedures

J. Ruhlmann, C. Reichel, H. Biersack, 1996, European Journal of Nuclear Medicine.

Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma.

H. Kirchner, M. Fenner, H. Poliwoda, 1993, European journal of cancer.

[Scintigraphy of the parathyroid glands with 99mTc-MIBI].

T. Sudhop, H. Biersack, F. Grünwald, 1995, Medizinische Klinik.

Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging

H. Biersack, H. Bender, F. Grünwald, 1996, European Journal of Nuclear Medicine.

Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.

H. Biersack, H. Bender, J. Mezger, 1999, Hybridoma.

[Changes in the blood picture after radioiodine therapy of thyroid cancer].

R. Fimmers, A. Bockisch, H. Biersack, 1994, Medizinische Klinik.

Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.

J. Ruhlmann, H. Biersack, H. Bender, 1997, Anticancer research.

Scintimammography with Tc-99m MIBI in patients with suspicion of primary breast cancer.

H. Biersack, H. Palmedo, F. Grünwald, 1996, Nuclear medicine and biology.

"High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.

H. Biersack, H. Bender, H. Palmedo, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

â€œHigh-Doseâ€(cid:157)Radioiodine Therapy in Advanced Differentiated Thyroid Carcinoma

H. Bender, H. Palmedo, A. Schomburg, 2006 .

Low-Dose lnterleukin-2 in Combination with Interferon-α Effectively Modulates Biological Response in vivo

H. Kirchner, H. Poliwoda, T. Menzel, 1993 .